Is PRLD or KLRS more profitable?

Kalaris Therapeutics' return on equity of -71.71% beat Prelude Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Prelude Therapeutics N/A -75.35% -44.39% Kalaris Therapeutics N/A -71.71% -42.95%

Does the media prefer PRLD or KLRS?

In the previous week, Kalaris Therapeutics had 1 more articles in the media than Prelude Therapeutics. MarketBeat recorded 6 mentions for Kalaris Therapeutics and 5 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 1.39 beat Kalaris Therapeutics' score of 0.84 indicating that Prelude Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kalaris Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SVA or KLRS?

Kalaris Therapeutics has a consensus target price of $18.75, indicating a potential upside of 359.56%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kalaris Therapeutics is more favorable than Sinovac Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Kalaris Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88

Which has preferable earnings and valuation, SVA or KLRS?

Kalaris Therapeutics has lower revenue, but higher earnings than Sinovac Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A Kalaris Therapeutics N/A N/A -$43.44M -$2.15 N/A

Is SVA or KLRS more profitable?

Sinovac Biotech's return on equity of 0.00% beat Kalaris Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sinovac Biotech N/A N/A N/A Kalaris Therapeutics N/A -71.71% -42.95%

Does the media favor SVA or KLRS?

In the previous week, Kalaris Therapeutics had 4 more articles in the media than Sinovac Biotech. MarketBeat recorded 6 mentions for Kalaris Therapeutics and 2 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.93 beat Kalaris Therapeutics' score of 0.84 indicating that Sinovac Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sinovac Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kalaris Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, KLRS or LXEO?

Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kalaris Therapeutics N/A N/A -$43.44M -$2.15 N/A Lexeo Therapeutics N/A N/A -$99.96M -$1.45 N/A

Is KLRS or LXEO more profitable?

Lexeo Therapeutics' return on equity of -41.85% beat Kalaris Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kalaris Therapeutics N/A -71.71% -42.95% Lexeo Therapeutics N/A -41.85% -38.03%

Does the media favor KLRS or LXEO?

In the previous week, Lexeo Therapeutics had 2 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 8 mentions for Lexeo Therapeutics and 6 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.84 beat Lexeo Therapeutics' score of 0.72 indicating that Kalaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kalaris Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexeo Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, DMAC or KLRS?

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DiaMedica Therapeutics N/A N/A -$32.77M -$0.72 N/A Kalaris Therapeutics N/A N/A -$43.44M -$2.15 N/A

Is DMAC or KLRS more profitable?

Kalaris Therapeutics' return on equity of -71.71% beat DiaMedica Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets DiaMedica Therapeutics N/A -77.76% -69.43% Kalaris Therapeutics N/A -71.71% -42.95%

Does the media prefer DMAC or KLRS?

In the previous week, DiaMedica Therapeutics had 14 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 20 mentions for DiaMedica Therapeutics and 6 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.84 beat DiaMedica Therapeutics' score of 0.75 indicating that Kalaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DiaMedica Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kalaris Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is KLRS or IPSC more profitable?

Century Therapeutics' return on equity of -49.51% beat Kalaris Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kalaris Therapeutics N/A -71.71% -42.95% Century Therapeutics N/A -49.51% -38.09%

Does the media favor KLRS or IPSC?

In the previous week, Kalaris Therapeutics had 1 more articles in the media than Century Therapeutics. MarketBeat recorded 6 mentions for Kalaris Therapeutics and 5 mentions for Century Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.84 beat Century Therapeutics' score of -0.02 indicating that Kalaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kalaris Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Century Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Kalaris Therapeutics (KLRS) Competitors

$4.08 +0.20 (+5.15%)

Closing price 04:00 PM Eastern

Extended Trading

$4.12 +0.04 (+0.86%)

As of 04:10 PM Eastern

Compare

KLRS vs. PRLD, SVA, LXEO, DMAC, and IPSC

Should you buy Kalaris Therapeutics stock or one of its competitors? Kalaris Therapeutics's main competitors and comparable companies include Prelude Therapeutics (PRLD), Sinovac Biotech (SVA), Lexeo Therapeutics (LXEO), DiaMedica Therapeutics (DMAC), and Century Therapeutics (IPSC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kalaris Therapeutics compare to Prelude Therapeutics?

Prelude Therapeutics (NASDAQ:PRLD) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

79.7% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are held by institutional investors. 49.2% of Prelude Therapeutics shares are held by insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Kalaris Therapeutics has lower revenue, but higher earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	36.41	-$99.50M	-$1.00	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A

Prelude Therapeutics currently has a consensus price target of $7.67, indicating a potential upside of 38.14%. Kalaris Therapeutics has a consensus price target of $18.75, indicating a potential upside of 359.56%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kalaris Therapeutics is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Kalaris Therapeutics had 1 more articles in the media than Prelude Therapeutics. MarketBeat recorded 6 mentions for Kalaris Therapeutics and 5 mentions for Prelude Therapeutics. Prelude Therapeutics' average media sentiment score of 1.39 beat Kalaris Therapeutics' score of 0.84 indicating that Prelude Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prelude Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kalaris Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kalaris Therapeutics' return on equity of -71.71% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-75.35%	-44.39%
Kalaris Therapeutics	N/A	-71.71%	-42.95%

Prelude Therapeutics has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

Summary

Kalaris Therapeutics beats Prelude Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Sinovac Biotech?

Sinovac Biotech (NASDAQ:SVA) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

66.1% of Kalaris Therapeutics shares are owned by institutional investors. 12.8% of Sinovac Biotech shares are owned by company insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Kalaris Therapeutics had 4 more articles in the media than Sinovac Biotech. MarketBeat recorded 6 mentions for Kalaris Therapeutics and 2 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.93 beat Kalaris Therapeutics' score of 0.84 indicating that Sinovac Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sinovac Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kalaris Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sinovac Biotech's return on equity of 0.00% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
Kalaris Therapeutics	N/A	-71.71%	-42.95%

Kalaris Therapeutics has lower revenue, but higher earnings than Sinovac Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A

Sinovac Biotech has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market.

Kalaris Therapeutics has a consensus target price of $18.75, indicating a potential upside of 359.56%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kalaris Therapeutics is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Kalaris Therapeutics beats Sinovac Biotech on 8 of the 13 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Lexeo Therapeutics?

Kalaris Therapeutics (NASDAQ:KLRS) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

In the previous week, Lexeo Therapeutics had 2 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 8 mentions for Lexeo Therapeutics and 6 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.84 beat Lexeo Therapeutics' score of 0.72 indicating that Kalaris Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kalaris Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexeo Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Kalaris Therapeutics currently has a consensus price target of $18.75, indicating a potential upside of 359.56%. Lexeo Therapeutics has a consensus price target of $18.75, indicating a potential upside of 287.40%. Given Kalaris Therapeutics' higher possible upside, equities research analysts clearly believe Kalaris Therapeutics is more favorable than Lexeo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

Lexeo Therapeutics' return on equity of -41.85% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-71.71%	-42.95%
Lexeo Therapeutics	N/A	-41.85%	-38.03%

66.1% of Kalaris Therapeutics shares are owned by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are owned by institutional investors. 68.1% of Kalaris Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Lexeo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Kalaris Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A

Summary

Lexeo Therapeutics beats Kalaris Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Kalaris Therapeutics compare to DiaMedica Therapeutics?

DiaMedica Therapeutics (NASDAQ:DMAC) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77M	-$0.72	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A

DiaMedica Therapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market.

In the previous week, DiaMedica Therapeutics had 14 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 20 mentions for DiaMedica Therapeutics and 6 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.84 beat DiaMedica Therapeutics' score of 0.75 indicating that Kalaris Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DiaMedica Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kalaris Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by company insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Kalaris Therapeutics' return on equity of -71.71% beat DiaMedica Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.76%	-69.43%
Kalaris Therapeutics	N/A	-71.71%	-42.95%

DiaMedica Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 79.64%. Kalaris Therapeutics has a consensus target price of $18.75, suggesting a potential upside of 359.56%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kalaris Therapeutics is more favorable than DiaMedica Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Kalaris Therapeutics beats DiaMedica Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Kalaris Therapeutics compare to Century Therapeutics?

Kalaris Therapeutics (NASDAQ:KLRS) and Century Therapeutics (NASDAQ:IPSC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

In the previous week, Kalaris Therapeutics had 1 more articles in the media than Century Therapeutics. MarketBeat recorded 6 mentions for Kalaris Therapeutics and 5 mentions for Century Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.84 beat Century Therapeutics' score of -0.02 indicating that Kalaris Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kalaris Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Century Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Century Therapeutics' return on equity of -49.51% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-71.71%	-42.95%
Century Therapeutics	N/A	-49.51%	-38.09%

Kalaris Therapeutics presently has a consensus price target of $18.75, suggesting a potential upside of 359.56%. Century Therapeutics has a consensus price target of $4.75, suggesting a potential upside of 147.40%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Kalaris Therapeutics is more favorable than Century Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Kalaris Therapeutics has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

66.1% of Kalaris Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 68.1% of Kalaris Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Century Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Century Therapeutics has higher revenue and earnings than Kalaris Therapeutics. Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A
Century Therapeutics	$109.16M	3.17	-$9.58M	-$1.14	N/A

Summary

Kalaris Therapeutics beats Century Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Kalaris Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KLRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KLRS vs. The Competition

Export

Metric	Kalaris Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$92.36M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-2.02	6.29	211.09	21.74
Price / Sales	N/A	1,295.89	602.98	92.99
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	1.69	16.78	12.91	6.24
Net Income	-$43.44M	-$13.32M	$3.45B	$347.60M
7 Day Performance	0.25%	1.74%	1.12%	1.07%
1 Month Performance	-10.33%	1.60%	1.79%	1.03%
1 Year Performance	79.74%	56.43%	67.69%	20.77%

Kalaris Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KLRS Kalaris Therapeutics	3.9723 of 5 stars	$4.08 +5.2%	$18.75 +359.6%	+70.2%	$92.36M	N/A	N/A	110	Earnings Report Gap Up
PRLD Prelude Therapeutics	2.5071 of 5 stars	$4.84 +3.4%	$7.67 +58.4%	+491.0%	$385.38M	$12.14M	N/A	120	Positive News Earnings Report
SVA Sinovac Biotech	0.9343 of 5 stars	$6.47 flat	N/A	N/A	$368.91M	$386.01M	N/A	3,008	News Coverage High Trading Volume
LXEO Lexeo Therapeutics	2.1768 of 5 stars	$4.69 +3.1%	$18.75 +299.8%	+5.1%	$367.87M	N/A	N/A	58	Earnings Report
DMAC DiaMedica Therapeutics	1.755 of 5 stars	$6.74 -0.4%	$12.00 +78.0%	+12.5%	$363.15M	N/A	N/A	20	Trending News Earnings Report Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KLRS) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kalaris Therapeutics (KLRS) Competitors

KLRS vs. PRLD, SVA, LXEO, DMAC, and IPSC

How does Kalaris Therapeutics compare to Prelude Therapeutics?

Summary

How does Kalaris Therapeutics compare to Sinovac Biotech?

Summary

How does Kalaris Therapeutics compare to Lexeo Therapeutics?

Summary

How does Kalaris Therapeutics compare to DiaMedica Therapeutics?

Summary

How does Kalaris Therapeutics compare to Century Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRS vs. The Competition

Kalaris Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kalaris Therapeutics (KLRS) Competitors

KLRS vs. PRLD, SVA, LXEO, DMAC, and IPSC

How does Kalaris Therapeutics compare to Prelude Therapeutics?

Do insiders & institutionals believe in PRLD or KLRS?

Which has better valuation and earnings, PRLD or KLRS?

Do analysts rate PRLD or KLRS?

Does the media prefer PRLD or KLRS?

Is PRLD or KLRS more profitable?

Which has more risk and volatility, PRLD or KLRS?

Summary

How does Kalaris Therapeutics compare to Sinovac Biotech?

Do institutionals and insiders have more ownership in SVA or KLRS?

Does the media favor SVA or KLRS?

Is SVA or KLRS more profitable?

Which has preferable earnings and valuation, SVA or KLRS?

Which has more volatility & risk, SVA or KLRS?

Do analysts recommend SVA or KLRS?

Summary

How does Kalaris Therapeutics compare to Lexeo Therapeutics?

Does the media favor KLRS or LXEO?

Do analysts prefer KLRS or LXEO?

Is KLRS or LXEO more profitable?

Do institutionals & insiders have more ownership in KLRS or LXEO?

Which has more risk and volatility, KLRS or LXEO?

Which has better valuation and earnings, KLRS or LXEO?

Summary

How does Kalaris Therapeutics compare to DiaMedica Therapeutics?

Which has stronger earnings & valuation, DMAC or KLRS?

Which has more volatility & risk, DMAC or KLRS?

Does the media prefer DMAC or KLRS?

Do insiders & institutionals hold more shares of DMAC or KLRS?

Is DMAC or KLRS more profitable?

Do analysts rate DMAC or KLRS?

Summary

How does Kalaris Therapeutics compare to Century Therapeutics?

Does the media favor KLRS or IPSC?

Is KLRS or IPSC more profitable?

Do analysts prefer KLRS or IPSC?

Which has more volatility & risk, KLRS or IPSC?

Do insiders and institutionals have more ownership in KLRS or IPSC?

Which has preferable earnings and valuation, KLRS or IPSC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRS vs. The Competition

Kalaris Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools